Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

one-time loss from discontinue operations of $2 million during the same nine month period in 2006. Therefore, the net loss for the nine month period ending September 30, 2007 was $11.7 million versus a net loss of $1.9 million for the same period one year ago.

Balance Sheet and Debt Conversion

As of September 30, 2007, total assets were $34.4 million and total liabilities plus minority interest were $36.1 million. Subsequent to the quarter, the Company entered into an agreement on November 19, 2007, under which the principal amount of the $11.5 million Loan owed to RimAsia in connection with the Enshi acquisitions plus unpaid interest of $1,008,534, which totals $12,508,534 will be conditionally converted in full into 6,185,607 shares of senior redeemable convertible preferred shares of the Company. Thus the above listed liabilities would be decreased $12.5 million while the book value of the Company would increase by the same amount. Therefore current shareholder equity of negative $1.7 million, would improve to $10.8 million or $.30 per share based on the 36.5 million shares currently outstanding, and $.22 per fully diluted share with the preferred included.

These new preferred shares have an effective conversion price of $1.011. Additionally, the exercise price of $1.375 for the 12 million existing warrants exercisable into the Company's common stock previously issued to and currently held by RimAsia in connection with the extension of the Loan financing will be lowered to $1.26 per share and the term of the Existing Warrants extended to 4.5 years from the closing date. This is conditioned on the Company signing a letter of intent for acquisition of a new company or for the injection of the remaining 49% equity stake of Erye not already owned by the Company before January 15, 2008, having such acquisition closed before June 30, 2008.

Subsequent Events -- New Drug Development Agreement

Subsequent to the end of our third quarter o
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 In preparation for VARTECH 2014, ... cybersecurity company focused on authentication and SSO announced today ... ability to generate a OTP through the presentation of ... of user-based RFID authentication, 2FA,s solutions have leveraged the ... many years. RFID authentication is broadly deployed in healthcare ...
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... solid, liquid, and gasbut much stranger things ... phase transitions occur at the coldest temperatures ... can dramatically transform a material. , ... Brookhaven National Laboratory and Stony Brook University ... zero to isolate and probe these quantum ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) a ... to bio-pharmaceutical and healthcare organizations and the market leader ... drug development, announced today that its Board of Directors ... and Chief Executive Officer and as a member of ...
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... for the first quarter ended March 31, 2011. ... cash equivalents and investment securities of $23.1 million, as ...
... 2011 Frost & Sullivan Europe New Product Innovation Award ... for its state-of-the-art, high precision Novelda Impulse Radar transceiver ... Radar transceiver is a cutting-edge radar transceiver that incorporates ... unique penetration capabilities," remarks Frost & Sullivan Research Analyst ...
Cached Biology Technology:ERT Announces Appointment of New President and CEO 2ERT Announces Appointment of New President and CEO 3ERT Announces Appointment of New President and CEO 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 4Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Smithsonian scientists discover tropical tree microbiome in Panama 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... go through a laboratory version of boot camp may ... of Pittsburgh researchers. In essence, that's the concept behind ... a patient's own souped up dendritic cells, which have ... system in fighting the virus unique to that individual. ...
... affiliate of Harvard Medical School, are the first to ... angiogenesis (new blood vessel growth). The switch, they learned, ... two enzymes (known as PI3K and PLCg) that compete ... fulfill opposite missions, growth and regression, respectively. This finding ...
... at the Harvard Department of Ophthalmology's Schepens Eye Research ... the first to learn why the cornea, the clear ... unique phenomenon that makes vision possible. The key, say ... of the protein VEGFR-3 (vascular endothelial growth factor receptor-3) ...
Cached Biology News:T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3
... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: